Targets › SFTPB
1 program from 1 company in 1 trial: 1 Phase 4; Neurology; next expected readout Jul 2028.
Pulmonary surfactant-associated proteins promote alveolar stability by lowering the surface tension at the air-liquid interface in the peripheral air spaces. SP-B increases the collapse pressure of palmitic acid to nearly 70 millinewtons per meter. (UniProt, P07988)
Open in Phaseline: the race on SFTPB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Medical University of Graz | Poractant alfa (Curosurf®) Pulmonary surfactant replacement therapy | SFTPB, SFTPC, SFTPA1, SFTPA2 | Phase 4 | Neonates and Preterm Infants | Jul 2028 |
Neonates and Preterm Infants (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.